|1.||Ricart, Alejandro D: 3 articles (08/2011 - 03/2010)|
|2.||Cripe, Timothy P: 2 articles (10/2015 - 01/2013)|
|3.||Dombi, Eva: 2 articles (10/2015 - 01/2013)|
|4.||Jousma, Edwin: 2 articles (10/2015 - 01/2013)|
|5.||Ratner, Nancy: 2 articles (10/2015 - 01/2013)|
|6.||Rizvi, Tilat A: 2 articles (10/2015 - 01/2013)|
|7.||Wu, Jianqiang: 2 articles (10/2015 - 01/2013)|
|8.||Kim, Mi-Ok: 2 articles (10/2015 - 01/2013)|
|9.||Cheng, Hui: 2 articles (09/2015 - 01/2015)|
|10.||Chen, Zhong: 2 articles (09/2015 - 01/2015)|
01/01/2011 - "The downstream PI3K inhibitor, BEZ-235, effectively inhibited tumor cell growth in most of the cell lines tested, except the H1993 and H1650 cells, while the MEK inhibitor PD-325901 was effective in blocking the growth of KRAS mutated cell line H1734 but not H358, A549 and H460. "
01/01/2014 - "Noteworthy, the MAPK inhibitor PD0325901 alone did not significantly mediate tumor response in the context of a KRAS(G12D) model, and improved tumor responses resulted when combined with mTOR inhibition. "
04/01/2010 - "Treatment of athymic mice bearing TAMH flank tumors with vehicle or PD0325901 (20 mg/kg) revealed a significant reduction of MEK activity ex vivo 24 hours after a single PD0325901 dose. "
08/01/2012 - "Additionally, we tested efficacy of PD-0325901 in Kras(G12D-LSL) conditional GEMMs (genetically engineered mouse models) which are a valuable tool in translational research to study tumor progression. "
07/01/2012 - "These results provide a detailed study of the effects of PD0325901 in development and show that, unlike in cancer, which requires robust inhibition of MAPK signalling, a partial reduction in phospho-ERK1/2 activity is sufficient to moderate the developmental effects of BRAF(CFC) mutations."
|2.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/15/2010 - "A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer."
04/15/2010 - "To evaluate the efficacy of mitogen-activated protein kinase/extracellular signal-related kinase kinase inhibitor PD-0325901 in advanced non-small cell lung cancer patients who had experienced treatment failure after, or were refractory to, standard systemic therapy. "
|3.||Colorectal Neoplasms (Colorectal Cancer)
06/01/2014 - "Combination PI3K/MEK inhibition with NVP-BKM120 and PD-0325901 induced tumor regression in a mouse model of PIK3CA wild-type, KRAS mutant colorectal cancer, which was mediated by inhibition of mTORC1, inhibition of MCL-1, and activation of BIM. "
01/01/2013 - "The in vivo anti-tumour efficacy and PK-PD properties of the MEK inhibitor PD 0325901 and the PI3K inhibitor GDC-0941, alone and in combination, were evaluated in HCT116 and HT29 human colorectal cancer xenograft tumour-bearing mice, and [(18)F]-FLT PET investigated in mice bearing HCT116 xenografts. "
04/10/2012 - "This study evaluated the MEK inhibitors AZD6244 and PD0325901, alone and in combination with the dual mTOR/PI3K inhibitor NVP-BEZ235 or the PI3K inhibitor GDC-0941, in three colorectal cancer cell lines. "
|4.||Thyroid Neoplasms (Thyroid Cancer)
08/01/2008 - "PD0325901 could inhibit invasion and anchorage-independent growth of thyroid cancer cells independently of the type of genetic alterations. "
08/01/2008 - "We examined the effects of PD0325901 on a variety of cellular and molecular activities of thyroid cancer cell lines with distinct genotypes. "
08/01/2008 - "The objective of this study was to use a potent new-generation MEK inhibitor PD0325901 to further investigate the therapeutic potential of specifically targeting MEK in the MAP kinase pathway for thyroid cancer. "
08/01/2008 - "The MEK inhibitor PD0325901 has a wide range of potent inhibitory effects on thyroid cancer cells, some of which seemed to be genotype-selective, consistent with the results previously observed with an early-generation MEK inhibitor, CI-1040. "
08/01/2008 - "PD0325901 remarkably inhibited MAP kinase pathway signaling in the thyroid cancer cells tested. "
|5.||Stomach Neoplasms (Stomach Cancer)
|2.||Protein Kinases (Protein Kinase)
|3.||2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamide
|7.||2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidine
|8.||Neurofibromin 1 (Neurofibromin)
|1.||Heterologous Transplantation (Xenotransplantation)